drugset / Trial / NCT05812677
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer
Phase 0
Unknown
20 enrolled
Shanghai Yunying Medical Technology
Shanghai 10th People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory Cervical and Endometrial Cancer.
Timeline
- Start
- 2023-02-06
- Primary completion
- 2025-02-06
- Completion
- 2026-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | R130 | Unknown | 1 ml | Other |
| Subject | R130 | Unknown | 4 ml | Other |